目次

Table of Contents

List of Tables

List of Figures
Introduction
Global Markets Direct Report Coverage
Venous Leg Ulcers (Crural Ulcer) - Overview
Venous Leg Ulcers (Crural Ulcer) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Venous Leg Ulcers (Crural Ulcer) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Venous Leg Ulcers (Crural Ulcer) - Companies Involved in Therapeutics Development
Aurealis Therapeutics AG
CytoTools AG
Energenesis Biomedical Co Ltd
GangaGen Biotechnologies Pvt Ltd
Hypo-Stream Ltd
Mallinckrodt Plc
MediWound Ltd
NovaLead Pharma Pvt Ltd
Promore Pharma AB
QBiotics Group Ltd
Reponex Pharmaceuticals AS
RHEACELL GmbH & Co KG
Tissue Repair Pty Ltd
Venturis Therapeutics Inc
Zhittya Genesis Medicine Inc
Venous Leg Ulcers (Crural Ulcer) - Drug Profiles
Amesanar - Drug Profile
Product Description
Mechanism Of Action
History of Events
AUP-16 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - Drug Profile
Product Description
Mechanism Of Action
History of Events
CVBT-141 - Drug Profile
Product Description
Mechanism Of Action
CVBT-141B - Drug Profile
Product Description
Mechanism Of Action
diperoxochloric acid - Drug Profile
Product Description
Mechanism Of Action
History of Events
EBC-1013 - Drug Profile
Product Description
Mechanism Of Action
ENERGIF-703 - Drug Profile
Product Description
Mechanism Of Action
EscharEx - Drug Profile
Product Description
Mechanism Of Action
History of Events
EscharEx Second Generation - Drug Profile
Product Description
Mechanism Of Action
History of Events
FGF-1 - Drug Profile
Product Description
Mechanism Of Action
molgramostim - Drug Profile
Product Description
Mechanism Of Action
History of Events
NLP-328 - Drug Profile
Product Description
Mechanism Of Action
P-128 - Drug Profile
Product Description
Mechanism Of Action
ropocamptide - Drug Profile
Product Description
Mechanism Of Action
History of Events
sodium hypochlorite - Drug Profile
Product Description
Mechanism Of Action
Stem Cell Therapy for Venous Leg Ulcers - Drug Profile
Product Description
Mechanism Of Action
History of Events
TR-987 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Venous Leg Ulcers (Crural Ulcer) - Dormant Projects
Venous Leg Ulcers (Crural Ulcer) - Discontinued Products
Venous Leg Ulcers (Crural Ulcer) - Product Development Milestones
Featured News & Press Releases
Jan 24, 2022: MediWound announces positive topline results from its U.S. phase 2 trial of EscharEx for debridement of chronic wounds
Oct 25, 2021: Promore Pharma announces that scientific article has been published on clinical study results with ropocamptide for venous leg ulcers
Oct 19, 2021: From chronic to curable RHEACELL is developing a novel cell-therapy agent for the treatment of chronic venous ulcers
Jul 28, 2021: MediWound announces positive outcome of interim assessment for its EscharEx U.S. phase 2 adaptive design study
Jul 09, 2021: MediWound announces peer-reviewed paper detailing Escharex phase 2 randomized control trial results published in the online Wound Repair and Regeneration Journal
Jun 09, 2021: MediWound completes patient enrollment for interim assessment of its U.S. EscharEx phase 2 adaptive design study
Apr 22, 2021: MediWound enrolls first patient in phase 2 pharmacology study of EscharEx
Jan 11, 2021: MediWound provides progress update on its EscharEx clinical development program
Nov 20, 2020: Clarification of outcome in the clinical trial HEAL LL-37
Nov 19, 2020: Promore Pharma announces positive results from Phase IIb study of ropocamptide in the treatment of venous leg ulcers
Oct 08, 2020: The IND application of ENERGI-F703 for treating venous leg ulcers (VLU) has been approved by TFDA
Jul 14, 2020: Promore Pharma is granted a patent for ropocamptide in the US
Mar 24, 2020: Promore Pharma reached the targeted number of patients completing treatment in the HEAL LL-37 Phase IIb clinical trial
Dec 10, 2019: Promore Pharma has finalized recruitment of patients in HEAL LL-37 early
Dec 03, 2019: MediWound Initiates U.S. Phase 2 Adaptive design study of EscharEx for treatment of Venous Leg Ulcers
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Venous Leg Ulcers (Crural Ulcer), 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Aurealis Therapeutics AG, 2022
Venous Leg Ulcers (Crural Ulcer) - Pipeline by CytoTools AG, 2022
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Energenesis Biomedical Co Ltd, 2022
Venous Leg Ulcers (Crural Ulcer) - Pipeline by GangaGen Biotechnologies Pvt Ltd, 2022
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Hypo-Stream Ltd, 2022
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Mallinckrodt Plc, 2022
Venous Leg Ulcers (Crural Ulcer) - Pipeline by MediWound Ltd, 2022
Venous Leg Ulcers (Crural Ulcer) - Pipeline by NovaLead Pharma Pvt Ltd, 2022
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Promore Pharma AB, 2022
Venous Leg Ulcers (Crural Ulcer) - Pipeline by QBiotics Group Ltd, 2022
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Reponex Pharmaceuticals AS, 2022
Venous Leg Ulcers (Crural Ulcer) - Pipeline by RHEACELL GmbH & Co KG, 2022
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Tissue Repair Pty Ltd, 2022
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Venturis Therapeutics Inc, 2022
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Zhittya Genesis Medicine Inc, 2022
Venous Leg Ulcers (Crural Ulcer) - Dormant Projects, 2022
Venous Leg Ulcers (Crural Ulcer) - Dormant Projects, 2022 (Contd..1)
Venous Leg Ulcers (Crural Ulcer) - Discontinued Products, 2022

List of Figures
Number of Products under Development for Venous Leg Ulcers (Crural Ulcer), 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022